Evaluation of general condition before and after vitreous anti-VEGF drug administration for diabetic macular edema

Evaluation of general condition before and after vitreous anti-VEGF drug administration for diabetic macular edema - Evaluation of general condition before and after vitreous anti-VEGF drug administration for diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044287

Enrollment

150

Registered

2022-03-31

Start date

2020-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes with thickening of the central macula, which was defined as a central retinal thickness of 300 micrometer or more in the central subfield based on optical coherence tomography due to DME, were eligible for this study.

Exclusion criteria

Exclusion criteria: Active endophthalmitis or infection in either eye, uncontrolled glaucoma in either eye, or a history of stroke.

Design outcomes

Primary

Measure	Time frame
Compare HbA1c before and after intravitreal anti-VEGF drug administration, and see if HbA1c decreases.	—

Countries

Japan

Contacts

Public Contacthideyuki oshima

Fukui University Ophthalmology

fganka@med.u-fukui.ac.jp0776-61-8403

Outcome results